Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
Her2-Predict: Translational Study Of Tumor Samples From Ds8201-Au301 Ds8201-A-U302 And Ds8201-A-U303 Trials

trials will be asked to participate to HER2-PREDICT study offering them a new informed consent. In order to identify mRNA ERBB2 levels, we will evaluate by gene expression tumor samples from these

HER2
bone metastases
metastasis
primary tumor
breast cancer
  • 0 views
  • 05 Nov, 2020
  • 1 location
Assessing the Immunogenicity of pING-hHER3FL

receptor (HER) family including: HER1 (also known as EGFR), HER2, HER3 and HER4 (also known as ErbB2, ErbB3, and ErbB4 respectively) is an important receptor family for the development of many malignancies

HER2
metastasis
metastatic solid tumor
liver metastasis
hormone therapy
  • 0 views
  • 29 Jul, 2020
  • 1 location
Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer

suspicious metastatic lung cancer, including a 50% and 40% reduction in TTI for EGFR/ALK/ROS1/BRAF V600E subgroups and KRAS/LKB1/ERBB2/c-MET/BRAF non V600E subgroups, respectively. Investigators

KRAS
erbb2
cancer
LKB1
BRAF
  • 1 views
  • 02 Aug, 2020
  • 15 locations
Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks

One paraffin block is routinely used for Human Epidermal Growth Factor Receptor 2 (Her2/neu) immunohistochemistry (IHC) assessment. Here, investigators investigated if picking two or multiple paraffin blocks for Her2/neu evaluation is an economical, efficient and practical method, which may reduce false-negativity of Her2/neu IHC assessment due to intratumoral heterogeneity.

HER2
erbb2
gastric adenocarcinoma
human epidermal growth factor
adenocarcinoma
  • 7 views
  • 08 Nov, 2020
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast

suggested that low proliferation, hormone receptors expression, and lack of ERBB2 amplification were associated with a low risk of IBR in patients not receiving radiotherapy. A combined signature was tested

ki-67
lobular carcinoma
estrogen receptor
epidermal growth factor
carcinoma
  • 15 views
  • 02 Aug, 2020
  • 13 locations
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

HR+/HER2-negative BC represent 70% of all newly diagnosed breast tumours and are responsible for most recurrences and deaths due to this disease, and despite available standard therapies, 15-20% of hormone tumours recur at distant sites. As BC is a clinically and biologically heterogeneous disease, intrincsic subtype may play an important …

estrogen receptor
primary tumor
erbb2
estradiol
her2/neu-negative breast cancer
  • 0 views
  • 18 Jan, 2021
  • 15 locations
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

This is a prospective, single arm, open-label, unicenter, exploratory study in women with primary operable HER2-positive, HER2-enriched/ERBB2-high breast cancer according to PAM50 intrinsic

  • 0 views
  • 14 Oct, 2020
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

epidermal growth factor
estrogen receptor
palbociclib
cancer
her2/neu-negative breast cancer
  • 12 views
  • 26 Oct, 2020
  • 10 locations
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

To seek the efficacy signals of trastuzumab in combination with chemotherapy in pretreated patients of HER2 positive, relapse or metastatic carcinoma of digestive system as response rate (RR) determined by the Investigator using RECIST 1.1, and provide evidence for phase III clinical trial.

KRAS
ki-ras
carcinoma
digestive system tumor
platelet count
  • 7 views
  • 22 Jul, 2019
  • 1 location
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

-synonymous mutation in EGFR, ERBB2, or JAK2V617F (JAK2) will be eligible for the study. Very few phase 2 clinical trials have been performed in pediatrics using targeted agents in combination with

monoclonal antibody therapy
biologic agent
erbb2
cancer chemotherapy
cancer
  • 252 views
  • 08 Nov, 2020
  • 1 location